Pharmaceuticals APAC News & Press Release Distribution

Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results

– Advancing key programs in HBV, CNS, and HIV – – Received first BLA approval for COVID-19 Treatment in China and added to China's latest COVID-19 Diagnosis and Treatment Guidelines– – Multiple clinical value drivers expected across the portfolio in 2022 and beyond – – Cash, bank balances, an...

2022-03-23 07:20 3409

Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo® in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer

SUZHOU, China, March 22, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has establis...

2022-03-22 08:19 1946

Progresses Made in Series of Studies of Prevention and Control of COVID-19 with Lianhua Qingwen Capsules

SHIJIAZHUANG, China, March 21, 2022 /PRNewswire/ -- On March 19, the Media Briefing on Prevention and Control of COVID-19 with Lianhua Qingwen Capsules, a patented Chinese medicine developed and produced by Yiling Pharmaceutical, was convened inShijiazhuang City, Hebei Province, at which the in v...

2022-03-21 15:56 1752

Progresses Made in Series of Studies of Prevention and Control of COVID-19 with Lianhua Qingwen Capsules

Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

Offer Price of HK $24.80 per H Share To Raise Proceeds Up to HK$765 Million Focus on the R&D of HPV Vaccine Candidates Focus on In-house Research and Development of Novel Vaccines TAIZHOU, China, March 21, 2022 /PRNewswire/ -- The China-based novel vaccines company -Jiangsu Recbio Technology Co....

2022-03-21 14:41 2664

Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001

HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 inChina. Under the terms of the agreement, Lynk...

2022-03-18 13:28 4086

CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China

SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, announced today that the new drug application (...

2022-03-18 10:35 2624

CStone announced the global multi-regional registration trial of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma successfully reached the prespecified enrollment target

SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the global multi-regional ...

2022-03-18 08:37 2944

Led by OrbiMed, HiRO Raised Tens of Millions of US Dollars in Series A Financing, to Offer Multinational Global Clinical Development Strategy

SHANGHAI, March 18, 2022 /PRNewswire/ -- Harvest Integrated Research Organization ("HiRO" or the "Company") announced the completion of its Series A financing in the tens of millions of US dollars. This round of investment is led by OrbiMed, with the participation from existing shareholder, Fontu...

2022-03-18 08:00 2798

BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University

VANCOUVER, BC, March 17, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has entered into an agreement with Millipore-Sigma ("Millipore") a global Contract Development and Manufacturing Research Organization (...

2022-03-17 20:18 2868

First eye drops registered on the Australian Register of Therapeutic Goods (ARTG) to slow the progression of short-sightedness now available for children aged from 4 to 14 years old[1]

SYDNEY, March 17, 2022 /PRNewswire/ -- Aspen announced the Therapeutic Goods Administration (TGA) listing of a new medication to slow the progression of short-sightedness (myopia) in children and young teenagers. EIKANCE® 0.01% eye drops (atropine sulfate monohydrate 0.01%) are available on presc...

2022-03-17 17:00 2494

KeyZell start-up plans to reach 5 million euros in private investment and become the new biotech unicorn

MADRID, March 17, 2022 /PRNewswire/ -- KeyZell, a Spanish biotechnology company in the development phase of digital cancer treatments and tools, has just opened a private financing round which expects to achieve5 million euros to boost its projects and consolidate itself as one of the biotech sta...

2022-03-17 15:30 2470

Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma

SHANGHAI, March 17, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the year endedDecember 31st, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, afford...

2022-03-17 08:00 3007

Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma

SHANGHAI, March 16, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the year endedDecember 31st, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, afford...

2022-03-16 23:46 1823

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab

SAN DIEGO and SUZHOU, China, March 16, 2022 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced FDA clearance to proceed with a Phase1b/2 clinical trial of its anti-CTLA-4 monoclonal antib...

2022-03-16 19:00 2326

SSI SCHAEFER and Nahdi Medical Company launch the Middle East's first Automated Pharmaceutical Distribution Center facility in Saudi Arabia

RIYADH，Saudi Arabia, March 16, 2022 /PRNewswire/ -- SSI SCHAEFER , the world's leading provider of modular warehousing and logistics solutions, in cooperation with Nahdi Medical Company, the Kingdom's largest pharmaceutical retail chain, announced the implement...

2022-03-16 15:00 1742

Pasture Announces First Halal-Certified Surgical N95 Masks for Healthcare and Public Use

SINGAPORE, March 16, 2022 /PRNewswire/ -- Pasture Group, the leading global medical device manufacturer and pharmaceutical company inSingapore, unveils its accreditation as the world's top halal-certified US FDA-approved N95 mask producer for healthcare and public use.

2022-03-16 13:00 2085

Pasture Announces First Halal-Certified Surgical N95 Masks for Healthcare and Public Use

Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)

The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment inChina, through a randomized, double-blind and placebo-controlled trial In vitro tests shows that amubarvimab/romlusevimab combination retains neutralizing activity against...

2022-03-16 09:00 2447

Business Update on ASC10, an Oral Double Prodrug against COVID-19

HANGZHOU and SHAOXING, China, March 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the business update on its oral double prodrug ASC10 against Coronavirus Disease 2019 (COVID-19): By taking measures below, the manufacturing cost of ASC10 reduced significantly, which ...

2022-03-15 19:55 2124

Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress

Sirnaomics CTO Dmitry Samarsky, PhD, to Also Present OPT Congress Opening Remarks HONG KONG, March 15, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will pre...

2022-03-15 12:47 1949

Everest Medicines to Announce Full-Year 2021 Financial Results on March 29, 2022

SHANGHAI, March 15, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific markets, today announced that it will...

2022-03-15 09:00 2249